ArticleMaterials today. Bio2026
Phycocyanin-functionalized selenium nanoparticles attenuate osteoarthritis through ferroptosis suppression and modulation of the MAPK pathway.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a widespread degenerative disorder of the joints, in which chondrocyte oxidative stress, inflammatory responses, and ferroptosis play pivotal roles in disease progression, yet current therapeutic strategies remain largely insufficient. In this study, we developed Se@PC NPs as a nanotherapeutic and assessed its efficacy against OA by leveraging selenium's role in redox regulation and ferroptosis inhibition along with phycocyanin's dual antioxidant and anti-inflammatory properties. The resultant Se@PC NPs demonstrated excellent stability and biocompatibility. In IL-1β-stimulated ATDC5 cells, they effectively scavenged reactive oxygen species (ROS), suppressed iron accumulation and lipid peroxidation, and upregulated key ferroptosis-related proteins (GPX4 and SLC7A11). Se@PC NPs can also promote the synthesis of cartilage extracellular matrix by reducing the levels of pro-inflammatory cytokines and catabolic enzymes. Transcriptomic analysis revealed that Se@PC NPs modulate the MAPK signaling pathway, as well as pathways associated with ferroptosis and oxidative stress. Furthermore, Se@PC NPs preserved mitochondrial structural integrity and membrane potential, thereby alleviating mitochondrial dysfunction. In a murine model of destabilization of the medial meniscus (DMM), Se@PC NPs attenuated cartilage erosion and osteophyte formation, restored the expression of COL2A1 and GPX4, suppressed MMP13 and COX2. In summary, Se@PC NPs synergistically exert antioxidant, anti-ferroptotic, and anti-inflammatory effects, effectively delaying OA progression and presenting a promising nanotherapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.